IPO Databook: Ziyond Pharmaceutical (HK) - Jul 2026

133 Views11 Jul 2026 10:02

SUMMARY

Ziyond Pharmaceutical is a specialized topical dermatology company in China, offering category-leading products. It seeks HKEX listing to fund portfolio, manufacturing, and market expansion.
Revenue increased from RMB1,030,560 thousand in 2023 to RMB1,323,670 thousand in 2025, with adjusted net profit reaching RMB180,933 thousand in 2025.
Gross profit margin decreased from 71.8% in 2023 to 66.1% by March 31, 2026, while the debt-to-assets ratio increased to 64.9%.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream